Compound records
One record per compound. Identity data verified against primary chemical databases, every figure logged with the species and route it came from.
| Record | Strongest evidence |
|---|---|
| 5-Amino-1MQ5-Amino-1MQ: verified identity, the rodent NNMT record with species, route and sample size… | Animal onlyMouse, rat and cell-culture work only; zero registered human trials, and the two published oral bioavailability figures disagree elevenfold |
| 9-Me-BC (9-methyl-beta-carboline)9-Me-BC: identity verified against PubChem and FDA GSRS, the 1998 mouse study that found the… | Animal onlyRodent and cell-culture work only; no registered human trial and no published human data of any kind |
| ACE-031 (Ramatercept)Verified identity for ACE-031 (ramatercept), its four registered trials, the registry's own… | Human dataTwo published randomised human trials totalling 72 participants; development discontinued in 2013 and the molecule is approved nowhere |
| ACE-083 (Efmitermant Alfa)Verified identity for ACE-083 (efmitermant alfa), its four registered trials with posted… | Human dataThree published human trials totalling 216 participants, across a four-study programme of 278 registered enrolments; development ended in 2020 and the molecule is approved nowhere |
| AHK-CuAHK-Cu has one indexed primary study and one granted patent. Every figure carries species… | Animal onlyRodent hair-growth data exist only in four worked examples of a granted patent, not in peer-reviewed literature; the indexed record is one 2007 ex vivo and cell-culture paper; zero registered human trials |
| AICAR (Acadesine)Verified identity for AICAR (acadesine), the 4,043-patient CABG meta-analysis, the… | Human dataLarge randomised human trials exist, all intravenous and all in cardiac surgery, with smaller intravenous studies in haematology and type 2 diabetes and oral dosing confined to pharmacokinetic and anti-doping elimination work; not an approved medicine in any jurisdiction, prohibited in sport at all times, and no human study of exercise capacity has ever been registered or published |
| AOD-9604 (LAT-8881)Verified identity for AOD-9604, the 502-patient obesity trial that failed, and three… | Human dataRandomised placebo-controlled human trials with posted results; the four efficacy endpoints tested were not met; not an approved medicine |
| ARA-290 (Cibinetide)ARA-290 (cibinetide): verified identity, every human trial figure with population and route… | Human dataFour small randomised trials in patients plus one in healthy volunteers, largest 64 subjects, none longer than 12 weeks; not an approved medicine in any jurisdiction |
| ATX-304 (O-304)ATX-304 (O-304) evidence ledger: verified identity, the single published human trial, the… | Human dataOne published 28-day phase IIa trial (n=65); all other findings are rodent or in vitro |
| AdamaxAdamax has no published study of any kind: PubMed returns only machine-learning papers. Two… | No source foundNo primary literature on this molecule in any species or assay; every figure on this page was measured on the unmodified parent peptide or on unrelated adamantylated peptides |
| Albuterol (Salbutamol)Verified identity for albuterol (salbutamol) plus every trial figure logged with species… | Human dataRandomised human trials across four decades, from 1992 to 2026, including an eleven-week resistance-training trial; an approved bronchodilator, with no indication in current FDA labelling relating to muscle mass, fat mass or body composition, and no non-US register searched for this page |
| Aminotadalafil: An Evidence LedgerAminotadalafil, the tadalafil analogue found in adulterated supplements. What the primary… | In vitroAnalytical detection and structure-elucidation studies, plus one in vitro screen in which the compound was inactive; no pharmacology, no animal work, no human administration |
| Amlexanox (AA-673)Verified identity for amlexanox, the aphthous-ulcer label figures, the 42-patient diabetes… | Human dataRandomised human trials exist in aphthous ulcers, plus one 42-patient diabetes trial; both approved US products are listed as discontinued and the systemic tablet form was never approved in the United States |
| Aniracetam (Ro 13-5057)Aniracetam: verified identity, the 0.2% bioavailability figure traced to an unindexed… | Human dataSix placebo-controlled human studies published between 1980 and 1991, two of them negative; five carry PubMed's Randomized Controlled Trial publication type and one does not. Nothing since, no prospectively registered trial, and the trial that ended the Japanese approval was never published |
| BAM15BAM15 evidence ledger: verified identity, measured mouse pharmacokinetics, the rodent and C. | Animal onlyNo human study found in any journal or registry; mouse, rat, C. elegans and cell data only |
| BPC-157Verified identity for BPC-157, every rodent and human figure logged with species, route and… | Human dataThree small uncontrolled human reports totalling fewer than 30 subjects; no completed randomised controlled trial; not an approved medicine anywhere |
| Bemethyl (Bemitil)Bemethyl (bemitil) evidence ledger: verified identity, the Russian-language record, four years… | Human dataHuman studies exist but are almost entirely Russian-language, unregistered, and unreplicated outside the former USSR; not an approved medicine in the US or EU |
| Bromantane (Ladasten)Bromantane (Ladasten) evidence ledger: verified identity, rat dopaminergic and epigenetic… | Human dataHuman trials exist but are Russian-language only, unregistered, and unreplicated outside Russia |
| CJC-1295 (with and without DAC)Two different peptides share the name CJC-1295. Identity data, every trial figure with… | Human dataTwo small published pharmacology trials in healthy volunteers; the sole patient trial was terminated unpublished; not an approved medicine anywhere |
| Cagrilintide (AM833)Cagrilintide (AM833): verified identity and sequence, receptor pharmacology, rodent data, and… | Human dataPublished phase 1, phase 2 and phase 3 randomised trials in thousands of participants; not an approved medicine in any jurisdiction |
| Cardarine (GW-501516)Verified identity for Cardarine (GW-501516), the four published human lipid trials, the two… | Human dataFour published human trials, largest n=268, longest 12 weeks, all lipid endpoints; development terminated on two 104-week rodent carcinogenicity studies published only as conference abstracts; not an approved medicine anywhere, prohibited in sport at all times |
| Cardiogen (AEDR)Verified identity for Cardiogen (AEDR, Ala-Glu-Asp-Arg), the expired 2004 patent that is its… | Animal onlyRodent, guinea pig and cell-culture work only; the principal cardiac data sit in a patent specification, not a journal; zero registered human trials |
| Cartalax (AED)Verified identity for Cartalax (AED), the cartilage claim traced to one Russian patent, and… | Animal onlyRat kidney and bone experiments whose abstracts state no group sizes, plus human-cell culture work; no trial of the tripeptide in people, and zero registered studies anywhere |
| Cerebrolysin (FPF 1070)Cerebrolysin is a porcine brain hydrolysate. Verified identity, the Cochrane readings of the… | Human dataRandomised placebo-controlled human trials, one with 1,070 participants; no United States marketing approval |
| ClenbuterolClenbuterol evidence ledger: verified identity, the randomised trials in humans, the… | Human dataRandomised placebo-controlled human trials exist in two groups — late-onset Pompe disease and adults with overweight or obesity — plus one randomised crossover in eleven healthy men; no human approval in the United States, where the only FDA approval is veterinary |
| CyclazodoneCyclazodone (cyclopropylpemoline): verified identity, the 1971 Dausse patent that holds nearly… | Animal onlyMouse and rat findings, most of them in a 1971 patent rather than peer-reviewed literature, plus human in vitro metabolism and protein-binding data on the N-methyl analogue; no human study of any kind |
| DSIP (Delta Sleep-Inducing Peptide)Verified identity for DSIP, the 1977 rabbit nonapeptide. What the sleep trials measured, what… | Human dataSmall double-blind human trials from the 1980s and 1990s, mostly negative outside the originating collaboration; not an approved medicine |
| Dihexa (PNB-0408)Verified identity for Dihexa (PNB-0408, ATH-1001), the 2025 retraction and 2021 notices of… | Animal onlyRodent, zebrafish and cell-culture work only; zero registered human trials |
| Eloralintide (LY3841136)Verified identity and trial record for eloralintide (LY3841136), a selective AMY1R agonist… | Human dataPublished Phase 1 and Phase 2 randomised trials; Phase 3 ongoing |
| EnclomifeneVerified identity data and every human trial figure for enclomifene, logged with population… | Human dataRandomised phase 2 and phase 3 trials in humans; not approved in any jurisdiction, refused by the EMA and never approved by the FDA |
| Epitalon (Epithalon)Verified identity for Epitalon (Epithalon), every telomere and lifespan figure with species… | Human dataA handful of unregistered human studies from a single institute; zero registered trials; FDA found no human safety or pharmacokinetic data |
| ExenatideVerified identity data for exenatide and the major trial figures, each logged with population… | Human dataLarge randomised outcome trials in humans; an approved medicine whose originator presentations are all recorded as discontinued |
| FOXO4-DRIFOXO4-DRI is a 46-residue D-retro-inverso peptide. Verified identity, what the 2017 mouse… | Animal onlyMouse, rat and human-cell work only; no registered human study has administered the peptide |
| Fasoracetam (NS-105)Fasoracetam (NS-105, NFC-1, AEVI-001): verified identity, the Japanese pharmacology, one… | Human dataPublished human studies exist: one uncontrolled open-label trial and one pharmacokinetic comparison. The four randomised placebo-controlled trials exist only as posted registry results. No approval for human use was located in any jurisdiction. |
| Fladrafinil (CRL-40,941)Fladrafinil (CRL-40,941) evidence ledger: verified identity, the 1984 Lafon patent data in… | Human dataOne published human study, a six-volunteer single-dose excretion study run for anti-doping method development, with no efficacy, safety or pharmacodynamic endpoint; no clinical trial of the compound is registered anywhere |
| GC-1 (Sobetirome)Verified identity for sobetirome (GC-1), the structural basis of its TRbeta preference, the… | Animal onlyRodent, monkey and cell data; both registered trials withdrawn at zero enrollment |
| GHK-Cu (Prezatide Copper)GHK-Cu identity checked against PubChem and FDA GSRS, with every trial figure logged by… | Human dataRandomised human trials exist, all topical and small, with results that contradict each other; not an approved medicine |
| Humanin (MT-RNR2): An Evidence LedgerHumanin, the 24-residue mitochondrial-derived peptide. What was measured, in which species… | Animal onlyCell and rodent models; all human data are observational biomarker measurements |
| IGF-1 LR3 (Long R3 IGF-I)Verified identity for IGF-1 LR3 (Long R3 IGF-I), the rat clearance data that contradict the… | Animal onlyRat, pig and mouse in vivo work plus rat, chicken, bovine and turkey cell culture; no primate has received this analogue in any retrieved study; zero registered human studies |
| ITPP (Myo-Inositol Trispyrophosphate)ITPP (OXY111A), the haemoglobin oxygen-affinity modifier. Verified identity, the 28-patient… | Human dataOne published phase Ib dose-escalation trial in 28 cancer patients; no controlled trial anywhere and no approval in any jurisdiction |
| Ipamorelin (NNC 26-0161)Verified identity data and every measured figure for ipamorelin, logged with species, route… | Human dataTwo phase 2 trials and one pharmacokinetic study in humans; not a component of any FDA-approved drug and absent from every pharmacopoeia FDA searched, and the larger trial has posted no results |
| J147J147: verified identity, the rodent and fly evidence base, a founding paper whose F statistics… | Animal onlyRodent, fly and cell-culture work only; a completed Phase 1 in 64 healthy volunteers has posted no results and has never been published; not approved for human use anywhere |
| KPV (alpha-MSH 11-13): An Evidence LedgerKPV, the C-terminal tripeptide of alpha-MSH. What was measured, in which species, and why five… | Animal onlyMouse, rat and rabbit models plus cell culture; no human trial registered on ClinicalTrials.gov, and no published pharmacokinetics in any species |
| KW-6356KW-6356 (sipagladenant): verified identity, eight registered trials with no posted results, a… | Human dataRandomised placebo-controlled trials in humans, including a published 168-patient phase 2a; six of eight registered trials produced no publication, no trial posted results, and development was discontinued in 2022 without regulatory approval anywhere |
| Kisspeptin (KP-10 and KP-54)Kisspeptin-10 and kisspeptin-54 are not the same molecule. Verified identity data and every… | Human dataRandomised human trials including two phase 2 in vitro fertilisation trials; not an approved medicine anywhere, and most trials used kisspeptin-54 rather than the decapeptide |
| L-THP (Levo-Tetrahydropalmatine)L-THP (levo-tetrahydropalmatine): verified identity, three registered trials including one… | Human dataRandomised placebo-controlled trials in humans exist in heroin dependence, cocaine use and schizophrenia; the largest is unpublished, and the compound is not an approved medicine in the United States or the European Union |
| LL-37 (Cathelicidin): An Evidence LedgerVerified identity for LL-37 (ropocamptide), the two randomised topical trials, the in vitro… | Human dataRandomised topical trials in humans plus a phase 1/2 intratumoural study with a registered enrolment of four and posted results for three; no approved product in any jurisdiction |
| Larazotide (AT-1001)Verified identity data and every trial figure for larazotide, logged with species, route and… | Human dataFour randomised human trials published, one meta-analysis, one small paediatric phase 2a; the phase 3 was terminated and never reported. Not an approved medicine anywhere. |
| MK-677 (Ibutamoren): An Evidence LedgerMK-677 (ibutamoren) has an unusually large human trial record. What those trials measured… | Human dataMultiple randomised placebo-controlled human trials including a two-year study; not an approved medicine in any jurisdiction located |
| MOTS-c: An Evidence LedgerMOTS-c, the 16-residue mitochondrial-derived peptide. What the rodent studies measured, why… | Animal onlyRodent and cell models throughout; every human dataset measures the endogenous peptide rather than administering it. One Phase 2a trial is recruiting with no posted results. |
| Mazdutide (IBI362)Registry-checked identity data and the published mazdutide trial figures, each logged with… | Human dataRandomised phase 3 trials in humans; approved in China only. No FDA record was returned by Drugs@FDA; no European authorisation was located, and the EMA register could not be queried directly. |
| Mecasermin (Increlex)Mecasermin (Increlex, rhIGF-1) is an approved medicine for one paediatric indication. Every… | Human dataApproved medicine in the US and EU for one paediatric indication; one small randomised placebo-controlled trial supports that indication and larger randomised trials in other conditions were negative or failed their primary endpoints |
| Melanotan-1 (Afamelanotide)Melanotan-1 is afamelanotide, approved as a 16 mg implant for erythropoietic protoporphyria.… | Human dataRandomised human trials and two marketing authorisations; every modern trial used a controlled-release implant, not an injection |
| Melanotan-2Verified identity for Melanotan-2, every figure from the three small controlled human studies… | Human dataOne Phase 1 dose-escalation pilot and two placebo-controlled crossover studies, 23 men in total, 1996-2000; not an approved medicine in any jurisdiction |
| Meldonium (Mildronate)Meldonium (mildronate) evidence ledger: verified identity, the carnitine-lowering mechanism… | Human dataRandomised trials exist in cardiac and stroke patients; the single placebo-controlled athlete trial is non-randomised and unindexed |
| Metatrutide (GLP-4)Metatrutide returns zero records from PubChem, FDA GSRS, PubMed and ClinicalTrials.gov. What… | No source foundNo study has administered this blend; the ledger rows below are for its two named components, tested separately |
| Methylene Blue (Methylthioninium Chloride)Methylene blue is an approved injectable drug with one indication. The principal trial, animal… | Human dataRandomised human trials across several indications, plus an intravenous product approved by the FDA for acquired methaemoglobinaemia; no oral methylene blue product holds FDA approval for any indication, and no non-US register was searched for this page |
| Mexidol (Emoxypine Succinate)Verified identity for Mexidol, the four placebo-controlled trials behind it, and the fact that… | Human dataRandomised double-blind placebo-controlled trials in humans, every one sponsored by the manufacturer and registered retrospectively; no United States or European marketing approval |
| Mirabegron (YM-178)Mirabegron is an approved overactive bladder drug studied for brown fat activation. Every… | Human dataSmall randomised and open-label human trials, plus a product approved by the FDA for overactive bladder; the US register carries no approval and no phase 3 programme for any metabolic indication |
| NAD+ (Nicotinamide Adenine Dinucleotide): An Evidence ReferenceNAD+ reference: verified identity, redox and consuming-enzyme mechanisms, a sourced claim… | Human dataBiochemistry characterised in human cells; the interventional human trials located studied precursors (NR, NMN), not NAD+ administered directly. |
| NSI-189 (Amdiglurax)NSI-189 (amdiglurax, ALTO-100): verified identity, two placebo-controlled depression trials… | Human dataTwo published placebo-controlled trials in depressed adults plus a third reported only in SEC filings; not approved for human use anywhere |
| Neboglamine (CR 2249)Verified identity for neboglamine (CR 2249, nebostinel), the five preclinical papers, the… | Animal onlyRat, mouse and gerbil models plus human cortical tissue in vitro; Phase 1 dosing was announced in 2007 but never published, and no trial is registered on ClinicalTrials.gov or the EU Clinical Trials Register |
| Nefiracetam (DM-9384)Nefiracetam: verified identity, three published human trials from one author group, the… | Human dataThree PubMed-indexed randomised trials, all in post-stroke populations and all from a single continuous author group; two reported no significant separation from placebo. Phase III was reached in Japan; trials of unstated phase were completed in China by August 2000 in preparation for a filing. Neither dataset is published. No marketing authorisation was located in any jurisdiction. |
| Noogutyl (Nooglutyl)Nooglutyl (ONK-10, CAS 112193-35-8): verified identity, the Russian rodent record, and why… | Animal onlyFor the free acid (PubChem CID 147523, CAS 112193-35-8) the strongest evidence is rodent; no human study of that substance exists. Randomised, placebo-controlled human trials exist only for the separately registered monocalcium salt (CAS 2365144-97-2, PubChem CID 86634601) given intravenously, all single-country and published in Russian-language journals. |
| Noopept (Omberacetam)Noopept (omberacetam): verified identity, the unsettled prodrug argument, one retracted paper… | Human dataPublished human studies exist, but none is PubMed-typed as randomised, none is registered in any trial registry, and all are Russian-language |
| Ostarine (MK-2866)Verified identity for ostarine (enobosarm), the 1.3 kg phase 2 figure everything quotes, two… | Human dataRandomised phase 2 and phase 3 trials in humans, several unpublished; not approved by any medicines regulator |
| Oxiracetam (ISF 2522)Oxiracetam: verified identity, a 500-patient 2026 trial that separated nothing from placebo… | Human dataTen placebo-controlled human reports of the racemate: nine published between 1985 and 1993, two of them negative and one finding no significant between-group difference on its main rating scale, with two pairs that appear to describe overlapping cohorts; the tenth, a 500-patient trial published in 2026 and the largest placebo-controlled trial of the racemate, was null on both coprimary endpoints. South Korea's medicines regulator recommended suspension of prescriptions in January 2023. Not approved in the United States and recorded by twelve official medicines control laboratories as not authorised for human use in the EU or Australia. |
| OxytocinOxytocin is an approved injectable obstetric medicine and an unapproved nasal spray. What each… | Human dataApproved injectable medicine with randomised obstetric trials enrolling tens of thousands; the separate intranasal behavioural literature is also human, but its founding trust result failed a well-powered registered replication and its largest autism trial missed its primary endpoint |
| P21 (P021)P021 (P21): verified identity from PubChem and FDA GSRS, the retracted Cerebrolysin… | Animal onlyRodent and cell-culture work only; no registered human trial and no published human data of any kind |
| PRL-8-53PRL-8-53: verified identity, the single 1978 human paper whose abstract omits every… | Human dataOne double-blind human paper from 1978, PubMed-typed among four types as a randomised controlled trial, never replicated and not retrievable in full text; not an approved medicine anywhere |
| PT-141 (Bremelanotide)Bremelanotide (PT-141) evidence ledger: RECONNECT phase 3 figures, a retracted trial in women… | Human dataTwo randomised phase 3 trials in humans and an FDA approval since June 2019 for one indication; the magnitude and validity of the measured effect are disputed in the peer-reviewed literature |
| PhenibutPhenibut evidence ledger: verified identity, rodent GABA-B and alpha-2-delta binding… | Human dataHuman clinical reports exist but are Russian-language and unregistered; Kupats 2020 records that none of the eleven trials it reviewed carries a statistical analysis in its abstract; no registered trial and no human pharmacokinetic study reporting a half-life was located |
| Phenylpiracetam (Fonturacetam)Phenylpiracetam (fonturacetam, carphedon): verified identity, the enantiomer problem, one… | Human dataPublished human studies exist; one indexed abstract describes a double-blind placebo-controlled randomised trial, all are Russian-language, and none is registered in ClinicalTrials.gov, the only registry queried |
| Pinealon (EDR)Verified identity for Pinealon (EDR), neuroprotection figures with what species, route and… | Human dataA small cluster of unregistered Russian occupational and geriatric studies with no described randomisation or blinding; zero registered trials; no pharmacokinetic data in any species |
| RAD-140 (Testolone)Verified identity for RAD-140 (vosilasarm), the phase 1 liver-enzyme signal, the drug-induced… | Human dataOne published phase 1 oncology trial plus a second trial recruiting; not approved by any regulator |
| Retatrutide (LY3437943)Verified identity data and every trial figure for retatrutide, logged with species, route… | Human dataRandomised phase 2 and phase 3 trials in humans; not an approved medicine |
| SLU-PP-332Verified identity for SLU-PP-332 and every reported figure logged with species, route, sample… | Animal onlyCell assays and mouse studies only; zero registered human trials |
| SNAP-8 (Acetyl Octapeptide-3)Verified identity for SNAP-8 (acetyl octapeptide-3), the four human studies that contain it… | Human dataAt least four published human studies contain it, in microneedle patches and in topical serums, always alongside other actives; no study at any level has tested it alone |
| SR-9009 (Stenabolic)Verified identity for SR-9009 (stenabolic), the rodent studies behind the endurance claim, the… | Animal onlyRodent, equine and cell work only; ClinicalTrials.gov returns zero registrations and no human trial has been published; all in vivo dosing was intraperitoneal; not an approved medicine anywhere and prohibited in sport at all times |
| SS-31 (Elamipretide)Verified identity for SS-31 / elamipretide plus every trial figure — including the failed… | Human dataMultiple randomised human trials, one FDA accelerated approval, one failed phase 3 |
| Selank (TP-7)Selank (TP-7) evidence ledger: verified identity, the two conflicting enkephalinase… | Human dataHuman trials exist, including PubMed-typed randomised controlled trials, but all are Russian-language, unregistered and unreplicated outside Russia |
| SemaglutideVerified identity data for semaglutide and the major trial figures, each logged with… | Human dataMultiple large randomised outcome trials in humans; an approved medicine, though material sold outside that supply chain is not the approved article |
| Semax (ACTH(4-7)PGP)Semax (ACTH(4-7)PGP): verified identity, rat pharmacokinetics, the Russian-language human… | Human dataPublished human studies exist, but they are Russian-language, mostly unblinded, and none is registered on ClinicalTrials.gov |
| SermorelinSermorelin is GHRH(1-29) amide. Two US approvals, both withdrawn in 2009. What the paediatric… | Human dataMulticentre and randomised human trials, most of them in growth-hormone-deficient children; both US approvals were withdrawn in 2009 and no approved product was found in any national register searched |
| Sunifiram (DM-235)Sunifiram (DM-235): verified identity, where the 1,000x-piracetam figure came from, the… | Animal onlyRodent behavioural work and brain-slice electrophysiology only; no pharmacokinetic study, no toxicology study, and no registered human trial of any kind |
| TAK-653TAK-653 (osavampator, NBI-1065845): verified identity, every registered trial, two conflicting… | Human dataRandomised placebo-controlled trials in humans including a 183-participant phase 2; the phase 2 exists only as a press release and a conference poster, and the molecule is approved nowhere |
| TB-500 (Thymosin Beta-4 17–23)TB-500 is a seven-residue fragment of thymosin beta-4, not the protein itself. Verified… | Animal onlyIn vivo data are equine and rodent only; FDA found no published study administering TB-500 to a human by any route |
| Tadalafil (IC-351)Verified identity for tadalafil, the PDE11 selectivity row that gets dropped, and the trial… | Human dataRandomised phase 3 trials across three approved indications, plus failed phase 3 and null crossover trials outside them; an approved prescription medicine, not an unapproved research compound |
| TesamorelinTesamorelin identity data verified against PubChem and FDA GSRS, plus every trial figure… | Human dataRandomised phase 3 trials in humans; approved by the FDA in 2010 for one narrow indication, and prohibited in sport |
| Tesofensine (NS-2330)Tesofensine evidence ledger: verified identity, the unresolved Lancet expression of concern on… | Human dataMultiple randomised human phase 2 trials; the principal obesity trial carries an unresolved expression of concern, and no phase 3 trial has been published anywhere |
| ThymalinVerified identity for Thymalin, a bovine thymus extract: mortality and cytokine figures with… | Human dataTwo placebo-controlled trials from one research lineage plus a 92-patient COVID-19 trial; zero registered trials; a state register file that lists the pharmacokinetics as not studied |
| Thymosin Alpha-1 (Thymalfasin)Verified identity data for thymosin alpha-1 and every trial figure logged with species, route… | Human dataMultiple randomised controlled trials in humans, including a null double-blind phase 3 trial in 1,106 adults; approved as a medicine in some jurisdictions but not in the United States, Japan or Europe outside Italy |
| Tirzepatide (LY3298176): verified identity and the evidence ledgerTirzepatide identity checked against FDA labeling and PubChem: 39 residues… | Human dataMultiple phase 3 randomised trials; mechanism work is in vitro and rodent |
| Tropisetron (ICS 205-930)Verified identity for tropisetron, its remeasured alpha7 nicotinic affinity, and the phase… | Human dataRandomised controlled trials in humans, including one phase 3; authorised as an antiemetic in jurisdictions outside the United States, never approved by the FDA |
| Vasoactive Intestinal Peptide (VIP): An Evidence LedgerVasoactive intestinal peptide: a one-minute plasma half-life, randomised placebo-controlled… | Human dataRandomised, placebo-controlled human trials exist; not an approved medicine in the United States, and the largest trial was stopped early for futility |
| Vistrutide (UBT251)Vistrutide is a vendor label for UBT251. Every published figure logged with population, route… | Human dataCompleted randomised phase 2 trials in humans, reported in one conference abstract and company announcements; no peer-reviewed publication; not an approved medicine anywhere |
| YK-11Verified identity for YK-11, the cell, rodent and equine studies that make up its published… | Animal onlyCell, rodent and equine work only; the sole human administration on record was a doping-control excretion study that measured metabolites, not effects |
| hCG (Human Chorionic Gonadotropin)hCG is an approved injectable hormone whose own label denies the weight-loss use it is famous… | Human dataRandomised human trials and an approved product label dating to 1974; the controlled obesity literature is overwhelmingly negative — the two positive reports are Asher and Harper 1973 and one unnamed trial among the twelve higher-scoring studies pooled by Lijesen 1995, while every replication attempt in the ledger found no difference against placebo — and no weight-loss trial has ever been registered |
| hMG (Human Menopausal Gonadotrophin)hMG is a urinary mixture standardised by bioassay; roughly 95 per cent of its LH-receptor… | Human dataLarge randomised human trials and approved product labels in several jurisdictions; the male indication exists on the United Kingdom label and not on the United States one, and the pooled comparison against recombinant FSH changed direction between the 2011 and 2026 Cochrane reviews, which pooled different comparators |
No records match that filter.